

ROBOTIC PROSTATECTOMY SPREADS PROSTATE CANCER CELLS

Studies show that prostate cancer cells are spread from robotic prostatectomy surgery in patients.

CORAL SPRINGS, FL, UNITED STATE, February 1, 2016 /EINPresswire.com/ -- "Studies have shown that showers of cancer cells are released into the bloodstream during the surgical treatment

٢٢

"Outrageously, the robotic device was able to garner an FDA "approval" without this device ever having been scientifically evidence-based tested for safety and effectiveness on a single patient."

Dr. Bert Vorstman

for prostate cancer. In fact, the increase in dispersed cancer cells because of surgery has correlated with a subsequent rise in PSA and therefore, failure to cure. This grave concern that the robotic prostatectomy actually promotes cancer cell spread simply adds to a long list of very troubling issues surrounding the radical prostatectomy," said Dr Bert Vorstman, a South Florida- based prostate cancer specialist.

He added, "In fact, for prostate cancer, the treatments are commonly worse than the disease itself and, aside from the robotic prostatectomy being associated with an incredible list of complications and having questionable lifesaving value, there have been endless lawsuits filed against the robotic

manufacturer and its surgeons. Shockingly, even patients have listed scores of self-reported harms on the FDA's (Food and Drug Administration) own product safety site, MAUDE (Manufacturer and User Facility Device Experience). Unfortunately, because of the site's complexity, this location records only about 8% of actual treatment harms. Even the Government oversight agency USPSTF (US Preventive Services Task Force), has issued a public health warning through their determination that PSA screen-based prostate cancer treatment benefits are outweighed by treatment harms. Harms and dangers which the robot device makers themselves admit to as their disclaimers are getting longer with each revision."

Furthermore said Dr. Vorstman, "As if this list of terrible complications associated with the radical prostatectomy could not be even more horrific, outrageously, the robotic device was able to garner an FDA "approval" without this device ever having been scientifically evidence-based tested for safety and effectiveness on a single patient with prostate cancer. Even worse, the device is used mostly to treat the common Gleason 6 "cancer", a disease which lacks the hallmarks of a cancer and, should not even be labelled a cancer."

Dr. Vorstman added, "Men need to be aware and protect themselves from over treatment. Only the 15% or so of high-grade prostate cancers have lethal potential and only these kind of prostate cancers demand detection and treatment. However, even for high-grade prostate cancer, the appalling complications and quality of life issues stemming from robotic prostatectomy surgery, along with the likelihood now that this surgery may actually be promoting prostate cancer spread, makes this toxic procedure an indefensible treatment option."

Dr. Bert Vorstman MD, MS, FAAP, FRACS, FACS is a urological surgeon and specialist at providing focal therapy for selected men with high-grade prostate cancer. For more information, visit

Keith Schilling Creative Behavior 7042698765 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2016 IPD Group, Inc. All Right Reserved.